Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Saturday 28 August 2021 10:47 am  |  Updated:  Friday 05 November 2021 12:55 pm

Delta Covid variant patients twice as likely to need hospital care

By: Edward Thicknesse

Add as a preferred source on Google
A new study into the Delta variant of Covid-19 suggests that those who contract the variant are twice as likely to require hospital care than those who contracted the original disease.

A new study into the Delta variant of Covid-19 suggests that those who contract the variant are twice as likely to require hospital care than those who contracted the original disease.

The findings, which were published in medical journal the Lancet, looked at cases of the disease between March and May.

However, it found that vaccination “leads to a similar relative reduction in the risk of hospitalisation for patients with the delta variant or the alpha variant”.

Experts said that the study proved why it was so important for everyone to get vaccinated against the disease.

Dr Gavin Dabrera, from Public Health England, which carried out the study, told the BBC: “We already know that vaccination offers excellent protection against Delta and, as this variant accounts for over 99 per cent of Covid cases in the UK, it is vital that those who have not received two doses of vaccine do so as soon as possible.

“It is still important that if you have Covid symptoms, stay home and get a PCR test as soon as possible.”

Scientists evaluated 43,338 Covid cases that occurred in the two month period, when both the Alpha and Delta variants were in circulation.

Most of those infected did not need hospital care, but a small proportion – 196 (2.3 per cent) of the people infected with Delta and 764 (2.2 per cent) of those with Alpha – did.

Risk of hospital admission was twice as high for individuals diagnosed with the Delta variant, compared to those with Alpha, after adjusting for differences such as age, sex and ethnicity.

The study comes as cases of Covid-19 continue to edge up in the UK, with over 38,000 cases and 100 deaths recorded yesterday.

Around 42m people, or about 78 per cent of adults, have now had two doses of a vaccine.

A recent study showed that two doses of the Pfizer vaccine had a 96 per cent effectiveness against vaccination, while for the Astrazeneca vaccine the figure is 92 per cent.

Read more

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus

Trending Articles

  • Citroën 2CV returns as a £13,000 electric car, and the timing is no accident

  • The former African gold miner taking on the billionaire Issa brothers

  • Barclays and Lloyds back calls to digitalise UK markets and unlock £33bn boost

  • Wimbledon: HMRC set to slap Sinner and Noskova with £1.6m tax bill

  • Music tycoon Simon Cowell sued by prominent City lawyer

More from City PM

  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire
  • Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

    Business Wire
  • cTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of Ambulation

    Business Wire
  • Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    Business Wire
  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire
  • Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

    Business Wire
  • John Healey’s principles will cost UK defence companies

    Opinion
    Breaking news concept with a digital world map and stock market graphs, illustrating global business trends and data analy...

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy · Facebook